Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety.
Mahmoud KandeelMohamed A MorsyKhalid M AlkhodairSameer AlhojailyPublished in: Inflammopharmacology (2024)
JAK inhibitors demonstrated superior efficacy in improving the functional status and reducing the disease activity in RA patients compared with TNF inhibitors. Both drug classes exhibited comparable safety profiles for VTE and malignancies, though JAK inhibitors had a higher risk for thromboembolism.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- end stage renal disease
- interstitial lung disease
- ejection fraction
- juvenile idiopathic arthritis
- venous thromboembolism
- newly diagnosed
- chronic kidney disease
- emergency department
- prognostic factors
- systemic sclerosis
- electronic health record